From man to mouse and back again: advances in defining tumor AKTivities in vivo.

  • Restuccia D
  • Hemmings B
  • 14

    Readers

    Mendeley users who have this article in their library.
  • 15

    Citations

    Citations of this article.

Abstract

AKT hyperactivation is a common event in human cancers, and inhibition
of oncogenic AKT activation is a major goal of drug discovery programs.
Mouse tumor models that replicate AKT activation typical of human
cancers provide a powerful means by which to investigate mechanisms
of oncogenic signaling, identify potential therapeutic targets and
determine treatment regimes with maximal therapeutic efficacy. This
Perspective highlights recent advances using in vivo studies that
reveal how AKT signaling supports tumor formation, cooperates with
other mutations to promote tumor progression and facilitates tumor-cell
dissemination, focusing on well-characterized prostate carcinoma
mouse models that are highly sensitive to AKT activation. The implications
of these findings on the therapeutic targeting of AKT and potential
new drug targets are also explored.

Author-supplied keywords

  • Animals; Antineoplastic Agents
  • antagonists /&/ inhibitors/metabolism; Signal Tra
  • drug effects
  • drug therapy/enzymology; PTEN Phosphohydrolase
  • metabolism; Phosphatidylinositol 3-Kinases
  • metabolism; Proto-Oncogene Proteins c-akt
  • pharmacology/therapeutic use; Humans; Mice; Neopl

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • David F Restuccia

  • Brian A Hemmings

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free